Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The case of CO signaling: why the jury is still out
Stephen P.L. Cary, Michael A. Marletta
Stephen P.L. Cary, Michael A. Marletta
Published May 1, 2001
Citation Information: J Clin Invest. 2001;107(9):1071-1073. https://doi.org/10.1172/JCI12823.
View: Text | PDF
Commentary

The case of CO signaling: why the jury is still out

  • Text
  • PDF
Abstract

Authors

Stephen P.L. Cary, Michael A. Marletta

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
The potential interplay of NO and CO. Established interactions that lead...
The potential interplay of NO and CO. Established interactions that lead to physiological responses are shown in solid lines, and dashed lines indicate interactions where some experimental support exists. NOS catalyzes the formation of NO and citrulline from arginine. NO directly activates the soluble isoform of guanylate cyclase (sGC), leading to 400-fold increased activity. cGMP then activates a PKG cascade and cellular Ca2+ levels are lowered. In part, PKG potentiates calcium-activated potassium channels (KCa), and the resulting hyperpolarization inhibits voltage-gated Ca2+ channels (CaV). PKG also appears to directly inhibit CaV. HO catalyzes the formation of CO from iron protoporphyrin IX. Results from HO–/– mice suggest that CO action depends on NO. While CO has been shown to activate the α1β1 isoform of sGC, the activation is very weak compared with that of NO (14). The action of CO on KCa would also lead to a hyperpolarization and inhibition of CaV. Agonists such as acetylcholine (Ach) and phenylephrine act by increasing cellular Ca2+.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts